Edition:
United Kingdom

Foundation Medicine Inc (FMI.OQ)

FMI.OQ on NASDAQ Stock Exchange Global Select Market

81.10USD
18 May 2018
Change (% chg)

$1.35 (+1.69%)
Prev Close
$79.75
Open
$80.15
Day's High
$81.90
Day's Low
$79.85
Volume
61,125
Avg. Vol
105,506
52-wk High
$87.05
52-wk Low
$31.70

Select another date:

Wed, May 2 2018

BRIEF-Foundation Medicine Q1 Loss Per Share $1.02

* FOUNDATION MEDICINE ANNOUNCES 2018 FIRST QUARTER RESULTS AND RECENT HIGHLIGHTS

BRIEF-Dian Diagnostics In Separate Agreements With Foundation Medicine, F. Hoffmann-La Roche

* SAYS IT SIGNS SEPARATE AGREEMENTS WITH FOUNDATION MEDICINE INC, F. HOFFMANN-LA ROCHE LTD ON TUMOUR TREATMENT Source text in Chinese: https://bit.ly/2FlRDHB Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Foundation Medicine's New Liquid Biopsy Assay Granted Breakthrough Device Designation By U.S. FDA

* FOUNDATION MEDICINE'S NEW LIQUID BIOPSY ASSAY GRANTED BREAKTHROUGH DEVICE DESIGNATION BY U.S. FOOD AND DRUG ADMINISTRATION

BRIEF-Foundation Medicine - Co, Guardant Health ‍Announced Agreement To Settle False Advertising Challenges

* FOUNDATION MEDICINE - CO, GUARDANT HEALTH ‍ANNOUNCED AGREEMENT TO SETTLE FALSE ADVERTISING CHALLENGES THAT COMPANIES HAD FILED AGAINST EACH OTHER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Foundation Medicine Reports Qtrly ‍loss Per Share $1.05

* FOUNDATION MEDICINE ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END RESULTS, RECENT HIGHLIGHTS AND 2018 OUTLOOK

BRIEF-Foundation Medicine Enters Into Amended And Restated Ex-US Commercialization Agreement With F. Hoffmann-La Roche Ltd

* FOUNDATION MEDICINE SAYS ON FEB 28, CO ENTERED INTO AMENDED AND RESTATED EX-US COMMERCIALIZATION AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD - SEC FILING

BRIEF-Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio

* FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO

BRIEF-Foundation Medicine Reports Preliminary 2017 Results

* - ‍ PRELIMINARY 2017 TOTAL REVENUE OF APPROXIMATELY $152.9 MILLION, A 31% YEAR OVER YEAR INCREASE​

BRIEF-Foundation Medicine Files For Potential Mixed Shelf, Size Not Disclosed

* FOUNDATION MEDICINE INC FILES FOR POTENTIAL MIXED SHELF, SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2BO42UB) Further company coverage:

Roche's Foundation Medicine wins FDA blessing for new cancer test

ZURICH Roche on Monday said its Foundation Medicine unit won U.S. Food and Drug Administration (FDA) approval for a test to help doctors understand the genetic profile of patients' tumours and guide them to effective therapies.

Select another date: